Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

Benzinga Newsdesk www.benzinga.com Neutral 54.1%

Neg 0% Neu 54.1% Pos 0%

Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight rating and announces Price Target of $345.